TY - JOUR
TI - The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases including COVID-19
AU - Gintoni, I.
AU - Adamopoulou, M.
AU - Yapijakis, C.
JO - In vivo (Athens, Greece)
PY - 2022
VL - 36
TODO - 1
SP - 13-29
PB - International Institute of Anticancer Research
SN - null
TODO - 10.21873/INVIVO.12672
TODO - dipeptidyl carboxypeptidase, genetic polymorphism;  genetics;  human;  renin angiotensin aldosterone system, Angiotensin-Converting Enzyme 2;  COVID-19;  Humans;  Peptidyl-Dipeptidase A;  Polymorphism, Genetic;  Renin-Angiotensin System;  SARS-CoV-2
TODO - Chronic and acute respiratory diseases pose a major problem for public health worldwide due to the high morbidity and mortality rates, while treatment options remain mostly symptomatic. The renin-angiotensin system (RAS) plays an important role in lung tissue, regulating pulmonary circulation and blood pressure, but also contributing to normal pulmonary function and development. Angiotensin-converting enzyme (ACE) and its homologous angiotensin-converting enzyme 2 (ACE2) are considered to be amongst the main RAS regulators and are highly expressed in the pulmonary vascular endothelium. This review discusses the impact of ACE and ACE2 functional gene polymorphisms on seven major pulmonary diseases, in terms of predisposition, course, and outcome, revealing their potential utility as both genetic markers and biomarkers. The discussed conditions include chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH), asthma, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), lung cancer and pulmonary sarcoidosis (PS), as well as SARS-CoV-2 viral infection and COVID-19 disease. © 2022 International Institute of Anticancer Research. All rights reserved.
ER -